Zhenlin Ju

65.8k total citations · 2 hit papers
73 papers, 3.7k citations indexed

About

Zhenlin Ju is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Zhenlin Ju has authored 73 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 20 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Zhenlin Ju's work include Advanced Biosensing Techniques and Applications (10 papers), Gene expression and cancer classification (9 papers) and Advanced Proteomics Techniques and Applications (9 papers). Zhenlin Ju is often cited by papers focused on Advanced Biosensing Techniques and Applications (10 papers), Gene expression and cancer classification (9 papers) and Advanced Proteomics Techniques and Applications (9 papers). Zhenlin Ju collaborates with scholars based in United States, China and Ireland. Zhenlin Ju's co-authors include Gordon B. Mills, Guang Peng, Yiling Lu, Jianfeng Shen, Yang Peng, Timothy A. Yap, Wei Zhao, Lulu Wang, Ronald B. Walter and Bryan T. Hennessy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Zhenlin Ju

69 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

2018 427 citations Jianfeng Shen, Wei Zhao et al. Cancer Research profile →
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

2015 358 citations Jianfeng Shen, Yang Peng et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhenlin Ju United States	35	2.3k	1.3k	672	599	395	73	3.7k
Benjamin G. Bitler United States	34	2.8k 1.2×	1.1k 0.8×	477 0.7×	759 1.3×	441 1.1×	100	3.9k
Barry R. Davies United Kingdom	33	2.1k 0.9×	1.0k 0.8×	424 0.6×	584 1.0×	343 0.9×	99	3.4k
Anne M. Øyan Norway	37	1.6k 0.7×	809 0.6×	347 0.5×	769 1.3×	163 0.4×	75	2.9k
Wenbin Wei United Kingdom	40	2.3k 1.0×	1.5k 1.2×	767 1.1×	714 1.2×	678 1.7×	134	4.5k
Dariush Etemadmoghadam Australia	18	1.7k 0.7×	1.1k 0.8×	304 0.5×	1.0k 1.7×	307 0.8×	23	3.1k
Michael Reedijk Canada	33	2.4k 1.1×	1.4k 1.0×	634 0.9×	731 1.2×	258 0.7×	50	3.7k
Honami Naora United States	30	2.2k 1.0×	864 0.7×	848 1.3×	693 1.2×	209 0.5×	90	3.7k
Olga Aprelikova United States	30	2.8k 1.2×	1.0k 0.8×	270 0.4×	1.1k 1.9×	163 0.4×	48	3.7k
E. Aubrey Thompson United States	42	3.3k 1.4×	1.6k 1.2×	504 0.8×	1.2k 2.0×	481 1.2×	112	5.0k
Giovanna Chiorino Italy	37	3.0k 1.3×	1.3k 1.0×	578 0.9×	1.3k 2.1×	315 0.8×	113	4.8k

Countries citing papers authored by Zhenlin Ju

Since Specialization

Citations

This map shows the geographic impact of Zhenlin Ju's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenlin Ju with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenlin Ju more than expected).

Fields of papers citing papers by Zhenlin Ju

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenlin Ju. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenlin Ju. The network helps show where Zhenlin Ju may publish in the future.

Co-authorship network of co-authors of Zhenlin Ju

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenlin Ju. A scholar is included among the top collaborators of Zhenlin Ju based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenlin Ju. Zhenlin Ju is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Juan, et al.. (2025). Genome-Wide Identification of CBL Gene Family and RNA-Seq Analysis Under Alkaline Stress in Poplar. Forests. 16(2). 200–200.

Li, Jun, Wei Liu, Kamalika Mojumdar, et al.. (2024). A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies. Nature Cancer. 5(10). 1579–1595. 6 indexed citations

Iwaya, Takeshi, Noriyuki Sasaki, Masashi Fujita, et al.. (2021). Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. British Journal of Cancer. 124(9). 1556–1565. 7 indexed citations

Jaiswal, Ashvin R., Arthur Liu, Shivanand Pudakalakatti, et al.. (2020). Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research. 8(11). 1365–1380. 43 indexed citations

Sasaki, Noriyuki, Takeshi Iwaya, Masashi Fujita, et al.. (2020). Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. PLoS ONE. 15(10). e0239966–e0239966. 4 indexed citations

Shen, Jianfeng, Wei Zhao, Zhenlin Ju, et al.. (2018). PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Research. 79(2). 311–319. 427 indexed citations breakdown →

Wang, Chao, Chao Gu, Kang Jin Jeong, et al.. (2017). YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor–Induced Activation of the PI3K Pathway. Cancer Research. 77(7). 1637–1648. 43 indexed citations

Xie, Victoria K., Zhiwei Li, Yongmin Yan, et al.. (2017). DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression. Clinical Cancer Research. 23(18). 5585–5597. 36 indexed citations

Dennison, Jennifer B., Maria Shahmoradgoli, Wenbin Liu, et al.. (2016). High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research. 22(20). 5068–5078. 26 indexed citations

10.

Shen, Jianfeng, Yang Peng, Leizhen Wei, et al.. (2015). ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discovery. 5(7). 752–767. 358 indexed citations breakdown →

11.

Li, Hua, Sarah Wheeler, Yong-Seok Park, et al.. (2015). Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts. Molecular Cancer Research. 14(3). 278–286. 44 indexed citations

12.

Cheung, Lydia W.T., Bryan T. Hennessy, Jie Li, et al.. (2011). High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. Cancer Discovery. 1(2). 170–185. 352 indexed citations

13.

Carey, Mark, Roshan Agarwal, C. Blake Gilks, et al.. (2010). Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy. Clinical Cancer Research. 16(10). 2852–2860. 45 indexed citations

14.

Park, Eun Sung, Rosalia Rabinovsky, Mark Carey, et al.. (2010). Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set. Molecular Cancer Therapeutics. 9(2). 257–267. 71 indexed citations

15.

Tsao, Twee, Steven M. Kornblau, Stephen Safe, et al.. (2010). Role of Peroxisome Proliferator-Activated Receptor-γ and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia. Cancer Research. 70(12). 4949–4960. 39 indexed citations

16.

Davies, Michael A., Katherine Stemke‐Hale, E. Lin, et al.. (2009). Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research. 15(24). 7538–7546. 159 indexed citations

17.

Sun, Hongxia, Wen-Cheng Chung, Zhenlin Ju, et al.. (2008). Cyclic AMP-Responsive Element Binding Protein– and Nuclear Factor-κB–Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis. Cancer Prevention Research. 1(5). 316–328. 57 indexed citations

18.

Liu, Geng, et al.. (2006). p21 delays tumor onset by preservation of chromosomal stability. Proceedings of the National Academy of Sciences. 103(52). 19842–19847. 85 indexed citations

19.

Walter, Ronald B., et al.. (2006). Genomic Resources for Xiphophorus Research. Zebrafish. 3(1). 11–22. 13 indexed citations

20.

Pritchard, Seth G., Zhenlin Ju, Edzard van Santen, et al.. (2000). The influence of elevated CO 2 on the activities of antioxidative enzymes in two soybean genotypes. Australian Journal of Plant Physiology. 27(11). 1061–1068. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact